Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia

2009 ◽  
pp. 1-4
Author(s):  
Mahmoud Shokry ◽  
Mohamed Bedaiwy ◽  
Mohamed Fathalla ◽  
Ali Alsemary ◽  
Sahar Elwakil ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
Early Predictors

Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia

2010 ◽  
Vol 89 (1) ◽  
pp. 143-146 ◽  
Author(s):  
Mahmoud Shokry ◽  
Mohamed A. Bedaiwy ◽  
Mohamed M.F. Fathalla ◽  
Ali Alsemary ◽  
Sahar Elwakil ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
Early Predictors

scholarly journals Maternal Serum Placental Growth Factor, Soluble Fms-Like Tyrosine Kinase-1, and Soluble Endoglin in Twin Gestations and the Risk of Preeclampsia—A Systematic Review

2020 ◽  
Vol 9 (1) ◽  
pp. 183 ◽  
Author(s):  
Katarzyna Kosinska-Kaczynska ◽  
Magdalena Zgliczynska ◽  
Szymon Kozlowski ◽  
Lukasz Wicherek
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Serum Levels ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
Cochrane Library ◽  
Original Research ◽  
Multiple Gestation ◽  
Soluble Endoglin ◽  
Twin Pregnancies

Multiple gestation is one of the key risk factors for the occurrence of preeclampsia (PE). Soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin are molecules involved in the process of angiogenesis with a proven role in the pathogenesis of PE. The aim of the review was to summarize available data on maternal serum levels of the above-mentioned factors and their usefulness in predicting PE in twin pregnancies. Only original research articles written in English were considered eligible. Reviews, chapters, case studies, conference papers, experts’ opinions, editorials, and letters were excluded from the analysis. No publication date limitations were imposed. The systematic literature search using PubMed/MEDLINE, Scopus, Embase, and Cochrane Library databases identified 338 articles, 10 of which were included in the final qualitative analyses. The included studies showed significant differences in maternal serum levels of the discussed factors between women with twin pregnancies with PE and those who did not develop PE, and their promising performance in predicting PE, alone or in combination with other factors. The identification of the most effective algorithms, their prompt introduction to the clinical practice, and further assessment of the real-life performance should become a priority.

scholarly journals Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor

2005 ◽  
Vol 90 (8) ◽  
pp. 4895-4903 ◽  
Author(s):  
Eiji Shibata ◽  
Augustine Rajakumar ◽  
Robert W. Powers ◽  
Robert W. Larkin ◽  
Carol Gilmour ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Vascular Dysfunction ◽  
Normal Pregnancy ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
Gestational Age At Delivery ◽  
Placental Protein

Context: An excess of the soluble receptor, fms-like tyrosine kinase 1 (sFlt-1) may contribute to maternal vascular dysfunction in women with preeclampsia by binding and thereby reducing concentrations of free vascular endothelial growth factor and placental growth factor (PlGF) in the circulation. The putative stimulus for increased sFlt-1 during preeclampsia, placental hypoxia due to poor perfusion, is common to both preeclampsia and idiopathic intrauterine growth restriction. However, the latter condition occurs without maternal vascular disease. Objective: We asked whether, as with preeclampsia, sFlt-1 is increased and free PlGF is decreased in villous placenta and maternal serum of normotensive women with small-for-gestational-age (SGA) neonates. Study Design: This was a case-control study using banked samples. Groups of women with SGA neonates (birth weight centile < 10th) and women with preeclampsia were matched to separate sets of normal pregnancy controls based on gestational age at blood sampling (serum) or gestational age at delivery (placenta). Results: sFlt-1 levels were higher in preeclamptics than controls (serum, P < 0.0001; placental protein, P = 0.03; placental mRNA, P = 0.007) but not increased in SGA pregnancies. PlGF was lower in both preeclampsia (serum, P < 0.0001; placental protein, P = 0.05) and SGA (serum, P = 0.0008; placental protein, P = 0.03) compared with their controls. PlGF in preeclampsia and SGA groups did not differ. Conclusions: These data are consistent with a role for sFlt-1 in the maternal manifestations of preeclampsia. In contrast to preeclampsia, sFlt-1 does not appear to contribute substantially to decreased circulating free PlGF in SGA pregnancies in the absence of a maternal syndrome.

scholarly journals Midgestation Maternal Serum 25-Hydroxyvitamin D Level and Soluble Fms-Like Tyrosine Kinase 1/Placental Growth Factor Ratio as Predictors of Severe Preeclampsia

Hypertension ◽  
2011 ◽  
Vol 58 (6) ◽  
pp. 1120-1125 ◽  
Author(s):  
Padmashree Chaudhury Woodham ◽  
Julia E. Brittain ◽  
Arthur M. Baker ◽  
D. Leann Long ◽  
Sina Haeri ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
Severe Preeclampsia ◽  
Hydroxyvitamin D ◽  
Factor Ratio ◽  
25 Hydroxyvitamin D

scholarly journals Comparison of Maternal Serum Soluble Fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio in Preeclamptic and Normotensive Pregnant Women

2019 ◽  
Vol 35 (2) ◽  
pp. 98-101
Author(s):  
Tuğba Kılık ◽  
Veli Mihmanlı ◽  
Sehtap Nazlı Kılıç Çetin ◽  
Orhan Şahin ◽  
Gökhan Demirayak ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Pregnant Women ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
Factor Ratio

Early predictors of placental dysfunction

2016 ◽  
pp. 25-28
Author(s):  
J.M. Melnik ◽  
◽  
A.A. Shlyahtina ◽  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Pregnant Women ◽  
Umbilical Artery ◽  
Placental Growth Factor ◽  
Vascular Endothelial ◽  
Endothelin 1 ◽  
Placental Dysfunction ◽  
Early Predictors ◽  
Endothelial Growth Factor

The article presents the predictors of placental dysfunction on the early stage of pregnancy. The objective: the search for prognostic markers and criteria for the occurrence of placental insufficiency in the early stages of the gestational process to optimize the pregnancy and labor with improved perinatal outcomes. Patients and methods. To solve this goal in the period from 2013 to 2015 were conducted a comprehensive survey of 334 pregnant women, which depending on the peculiarities of pregnancy and childbirth were divided into groups. The control group consisted of 236 pregnant women with uncomplicated gestational period, no morphological signs of placental dysfunction. The study group included 98 patients with a complicated pregnancy who had revealed violations of the fetal-placental relations, which was confirmed by morphological examination of the placenta in the postpartum period. Results. It was found that pregnant women with placental insufficiency in the first trimester of pregnancy have higher levels of interleukin-1B (IL-1v) and interleukin-3 (IL-3) in comparison with physiological pregnancy, as well as there is a direct significant correlation between IL-1v and pulsative index (PI) in the spiral (r=0.84) and uterine artery (r=0.77), and the inverse correlation between the level of IL-3 and PI in the terminal branches of the umbilical artery (r=-0.69). Verified an inverse relationship between the concentration of endothelin-1, the level of vascular endothelial growth factor (r=-0.87) and placental growth factor (r=-0.73), and also a direct link between the content of endothelin-1 and PI in spiral arteries (r=0.89), uterine artery (r=0.83) and the terminal branches of the umbilical artery (r=0.79). Conclusion. Thus, it is proven that early predictors of placental dysfunction can be considered the concentration of endothelin-1, vascular endothelial growth factor, placental growth factor, interleukin-1, interleukin-3, and the indices of pulsative index. Key words: placental dysfunction, predictors, endothelin-1, vascular endothelial growth factor, placental growth factor, interleukin, pulsative index.

Validation of Soluble Fms-Like Tyrosine Kinase-1 (sFlt-1) and Placental Growth Factor (PlGF) Assays on Cobas e602 System

2020 ◽  
Vol 154 (Supplement_1) ◽  
pp. S12-S13
Author(s):  
Nga Yeung Tang ◽  
Sarosh Rana ◽  
Kiang-Teck J Yeo
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Medical Center ◽  
Placental Growth Factor ◽  
Analytical Performance ◽  
Hypertensive Disorder ◽  
Limit Of Quantitation ◽  
Roche Diagnostics ◽  
Interference Studies ◽  
Plgf Ratio

Abstract Background Preeclampsia is a leading hypertensive disorder in pregnant women. The angiogenic biomarkers, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) ratio, have been shown to be associated with diagnosis and prediction of preeclampsia. The objective of this study is to validate the analytical performance of sFlt-1 and PlGF on the Cobas e602 system (Roche Diagnostics Corporation). Method Intra-day and inter-day precisions for both sFlt-1 and PlGF assays were assessed using quality control materials provided from Roche Diagnostics. The accuracies for both assays were assessed by running 60 patient samples, which have been previously analyzed on the Elecsys 411 analyzer (Roche Diagnostics Corporation) at the Beth Israel Deaconess Medical Center. Linearity studies for both assays were performed using patient plasma spiked with recombinant sFlt-1 and PlGF proteins (R&D systems). Hemolysis, icterus, lipemia and biotin interference studies were performed by spiking hemolysate, bilirubin, intralipid or biotin into either pooled patient plasma with detectable levels of sFlt-1 and PlGF or otherwise, patient plasma spiked with recombinant sFlt-1 and PlGF proteins. Results Total precisions for both assays demonstrated CVs of <5.0%. The sFlt-1 and PlGF assays demonstrated analytical measuring ranges of 3060,000 pg/mL and 79,000 pg/mL, respectively (r2 > 0.98). Lower limit of quantitation (10% CV) was 30 pg/mL for sFlt-1 and 7 pg/mL for PlGF, respectively. Interference studies showed sFlt-1 and PlGF were not significantly affected by hemolysis up to H-indices of 500 and 1000 respectively; both assays were not affected by bilirubin up to an I-index of 60, and lipemia up to an L-index of 2800. Biotin at concentrations >30 ng/mL caused significant negative bias for both sFlt-1 and PlGF assays. Comparison studies showed the following: Cobas e602 sFLT-1 = 1.09 [Elecsys 411 sFLT-1] +203 (r2=0.97, Sy/x=1234, n=58); Cobas e602 PlGF = 1.10 [Elecsys 411 PlGF] +47 (r2=0.99, Sy/x=22.1, n=58); Cobas e602 sFLT-1/PlGF ratio = 0.94 [Elecsys 411 sFLT-1/PlGF ratio] +3.5 (r2=0.91, Sy/x=50, n=58). Conclusion sFlt-1 and PlGF measured on Roche Diagnostics Cobas e602 system demonstrated excellent analytical performance and are acceptable for clinical use once approved in the US.

Sign in / Sign up

Export Citation Format

Share Document